tipo
- journal article
Glioblastoma Multiforme Targeted Delivery Of Docetaxel Using Bevacizumab-Modified Nanostructured Lipid Carriers Impair In Vitro Cell Growth And In Vivo Tumor Progression
Documento
- doi:10.1016/j.ijpharm.2022.121682
- http://dx.doi.org/10.1016/j.ijpharm.2022.121682
- http://dx.doi.org/10.1016/j.jipharm.2022.121682
- http://https://reader.elsevier.com/reader/sd/pii/S037851732200237X?token=7292314A0227F9C11C171673F8EFB782DBD5DD33D81D87DFD3968E7904F830E5A922ABD0D6B76FB7303D9A7B7EE15190&originRegion=us-east-1&originCreation=20220322131132][doi:10.1016/j.jipharm.2022.121682
- Visão geral
- Identidade
- Informação adicional documento
- Outro
- Ver todos
Visão geral
autores
data de publicação
- 2022-01-01